H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on ADMA Biologics to $5 from $4.50 and keeps a Buy rating on the shares post the Q2 report. The company’s positive EBITDA streak continues and its revenue beats Street consensus, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADMA:
- ADMA Earnings this Week: How Will it Perform?
- ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
- ‘Load Up,’ Says Raymond James About These 2 ‘Strong Buy’ Stocks
- ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
- ADMA Biologics receives FDA approval for ninth plasma collection center